Clinuvel Pharmaceuticals (ASX: CUV) — Company Overview, News & Financial Data
Clinuvel Pharmaceuticals is an Australian biopharmaceutical company developing drugs for genetic photosensitivity disorders.
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing treatments for patients with severe genetic, skin, and systemic disorders. Its lead commercial drug, SCENESSE (afamelanotide 16mg), is a controlled-release subcutaneous implant approved in Europe, the United States, and Australia for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company is expanding its clinical development program to evaluate melanocortins for additional photomedicine and central nervous system indications, including vitiligo, xeroderma pigmentosum, variegate porphyria, and arterial ischaemic stroke. CLINUVEL also develops PhotoCosmetics skincare products utilizing biomimetic technology for photoprotection and skin repigmentation.
Snapshot
Operations
Products and/or services of Clinuvel Pharmaceuticals
- Erythropoietic Protoporphyria Treatment: Commercialization of a subcutaneous controlled-release melanocortin peptide implant approved in multiple global markets to prevent phototoxicity and enabling light tolerance in adult patients suffering from erythropoietic protoporphyria, serving as the main revenue generator.
- Vitiligo Repigmentation Therapy: Clinical trial program evaluating systemic melanocortin analog therapy in combination with narrowband ultraviolet B light to induce repigmentation and restore skin color in patients affected by generalized vitiligo.
- Vascular and CNS Disorder Therapeutics: Clinical research investigating melanocortins to evaluate neuroprotective and therapeutic efficacy in acute neurological and systemic vascular emergencies, specifically targeting tissue damage caused by arterial ischaemic stroke.
- Severe Photodermatoses Treatments: Clinical evaluation of melanocortin therapies designed to enhance DNA repair mechanisms and provide photoprotection for patients diagnosed with genetic light-sensitivity conditions such as xeroderma pigmentosum and variegate porphyria.
- PhotoCosmetics Skincare Products: Development and commercialization of topical dermatological skincare formulations utilizing biomimetic peptide technology designed to deliver solar photoprotection, cellular skin barrier repair, and sunless melanogenesis induction.
- Translational Research and Manufacturing: In-house scientific research, formulation development, scale-up synthesis, and clinical manufacturing operations dedicated to novel melanocortin peptide formulations, liquid formulations, and targeted drug delivery systems across international research centres.
Clinuvel Pharmaceuticals executive team
- Dr. Philippe Jacques Wolgen M.B.A., M.D.CEO, MD & Director
- Mr. Peter VaughanChief Financial Officer
- Mr. Lachlan HayChief Operations Officer
- Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Chief Scientific Officer
- Mr. Malcolm BullHead of Australian Operations & Investor Relations
- Dr. Azza HamilaHead of Quality Assurance & Drug Safety
- Mr. David SolomonHead of Regulatory Affairs
- Ms. Claire Newstead-Sinclair C.A.Company Secretary